Results 171 to 180 of about 7,937 (220)

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study [PDF]

core   +1 more source

Left atrial appendage thrombi despite oral anticoagulation in transthyretin amyloid cardiomyopathy patients undergoing electrical cardioversion for atrial fibrillation or - flutter. [PDF]

Int J Cardiol Heart Vasc
Poledniczek M, Kronberger C, Gregshammer B, List L, Willixhofer R, Ermolaev N, Duca F, Rettl R, Binder C, Camuz Ligios L, Nitsche C, Eslami M, Graf S, Kastl S, Kastner J, Badr Eslam R, Hengstenberg C, Kammerlander A, Bergler-Klein J.   +18 more
europepmc   +1 more source

Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.

JAMA Cardiol
Alexander KM, Davis MK, Akinboboye O, Berk J, Bhatt K, Cappelli F, Cuddy SAM, Fontana M, Garcia-Pavia P, Gillmore JD, Griffin JM, Grodin JL, Judge DP, Khouri MG, Lam K, Masri A, Maurer MS, Obici L, Ruberg FL, Sarswat N, Shah K, Soman P, Stern L, Wright R, Xiong K, Cao X, Lystig T, Tamby JF, Castaño A, Katz L, Sinha U, Fox JC, Solomon SD, Grogan M.   +33 more
europepmc   +1 more source

Reply: Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. [PDF]

JACC Adv
Jaiswal V, Hanif M, Mashkoor Y, Prasad T, Fonarow GC.   +4 more
europepmc   +1 more source

Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage. [PDF]

Eur J Heart Fail
Damy T, Wang R, Maurer MS, Gillmore JD, Fontana M.   +4 more
europepmc   +1 more source

Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. [PDF]

Circulation
Fontana M, García-Pavía P, Grogan M, Shah SJ, Engelmann MDM, Hovingh GK, Kristen AV, Lim-Watson MZ, Malling B, Kar S, Revanna M, Sarswat N, Tsujita K, Alexander KM, Maurer MS.   +14 more
europepmc   +1 more source

Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. [PDF]

Eur Heart J
Gonzalez-Lopez E, Maurer MS, Garcia-Pavia P.   +2 more
europepmc   +1 more source

Wild-Type Transthyretin Amyloid Cardiomyopathy With Bone Marrow Involvement: Clinical Implications of Less Common Sites of Amyloid Deposition. [PDF]

Cureus
Kashiwagi Y, Suzuki K, Yoshinaga T, Sato M, Kawachi K, Ogawa K, Beppu M, Tokuda M.   +7 more
europepmc   +1 more source

Pharmacological Management of Transthyretin Amyloid Cardiomyopathy: Where We Are and Where We Are Going. [PDF]

J Clin Med
De Michieli L, Lupi A, Sinigiani G, Tietto A, Salvalaggio A, Branca A, Da Pozzo S, Rizzo S, Cecchin D, Perazzolo Marra M, Berno T, Corrado D, Briani C, Cipriani A.   +13 more
europepmc   +1 more source

Total atrial conduction time predicts new-onset atrial fibrillation in patients with transthyretin amyloid cardiomyopathy. [PDF]

Europace
Dal Passo B, Arzenton M, Cantone A, Fabbri G, Bonini J, Guidi Colombi G, Melpignano A, Marchini F, Izzo C, Pavasini R, Bertini M, Campo G, Serenelli M.   +12 more
europepmc   +1 more source